Supplement Perspectives
INS

New Research Supports Effects of Patented Lycopene Ingredient, Glutathione

<p>Two recent studies uncovered beneficial effects of supplement ingredients, including a patented form of lycopene and trans-resveratrol to reduce foot ulcers in diabetics and glutathione to prevent the onset and progression of non-alcoholic fatty liver disease (NAFLD).</p>

Two recent studies uncovered beneficial effects of supplement ingredients, including a patented form of lycopene and trans-resveratrol to reduce foot ulcers in diabetics and glutathione to prevent the onset and progression of non-alcoholic fatty liver disease (NAFLD).

A controlled human trial comparing a placebo to a patented form of lycopene and trans-resveratrol (t-RSV) formulation showed significant reduction in foot ulcers in diabetic patients. Orebro University Hospital and School of Health and Medical Sciences, Orebro Sweden, conducted the study. The study was published in the International Scholarly Research Notes Endocrinology.

Twenty-four participants with newly diagnosed diabetic foot ulcers (15 males, 9 females) were divided into placebo and t-RSV-treatment groups. Each group was given a either a placebo or the lycopene-trans-RSV combination twice a day for 60 days (in the same daily dosage sold in one over-the-counter (OTC) MedVital® Bio-Resveratrol™ capsule) on top of regular care and general diabetes treatment. At the end of the treatment period, the reduction of diabetic ulcer size was almost complete (95 percent) closure in the t-RSV group, significantly better as compared to the placebo (50 percent). T-RSV patients also demonstrated improved performance in the foot pressure test. The researchers note that these results need to be confirmed and further evaluated in larger clinical trials.

The results of a different recent multi-center, clinical study showed oral administration of glutathione (as L-glutathione reduced, GSH by KOHJIN Life Sciences) is effective against the onset and progress of NAFLD, and metabolic syndrome in the broader view. The study was presented at the International Liver Congress 2016 in Barcelona, Spain.

The study evaluated 34 subjects who were administered 300 mg/d of glutathione over a period of four months, and concluded with a comparison of both clinical parameters and image-view observation of steatosis (adipose degeneration), with the aid of transient elastography, according to each subject’s detailed profile before and after treatment with glutathione. The improvement in physical condition along both lines was decisive. Alanine aminotransferase (ALT) and controlled attenuation parameter (CAP/Fibroscan) levels—markers for NAFLD—were significantly lowered.

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish